poisar

Stocks · News reference

Jim Cramer Is Not Going To Go With This Consumer Cyclical Stock

BenzingaAvi Kapoor

Cramer avoids Polaris, likes Forgent despite its valuation, finds Symbotic too expensive, and hasn’t reviewed Corteva; all four stocks fell.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolJosh Kohn-Lindquist

    Stock Market Today, Oct. 6: Corteva Rallies 12% on Analyst Upgrade Following Spin Off

    Corteva (CTVA) surged 12% following a JPMorgan upgrade to Overweight with a $19 price target, implying 37% upside. The rally was fueled by the company's separation from Vylor and its inclusion in the S&P MidCap 400. Trading at 5.7x 2027 EBITDA, Corteva is positioned as a deep-value opportunity in crop protection, though legal liabilities from PFAS/PFOA concerns remain a risk factor.

  2. The Motley FoolScott Levine

    Why Corteva Stock Is Rocketing Higher Today

    Corteva stock surged 12.99% following JPMorgan's upgrade to overweight with a $19 price target, implying 53.3% upside from the previous closing price of $12.39. The upgrade comes after Corteva's October spinoff of its advanced seed and genetics business, with JPMorgan believing the company is now undervalued. The crop protection segment has shown strong growth, with over $1 billion in sales increases and 250 basis points of margin expansion from 2020-2025.